rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
10
|
pubmed:dateCreated |
1984-11-1
|
pubmed:abstractText |
Alpha-2 receptor activation mediates the inhibition of a number of gastrointestinal functions including gastric and intestinal secretions. Alpha-2 receptors are located in the brain and presynaptically on cholinergic nerve terminals; activation of either inhibits vagus nerve activity. Intestinal secretions are inhibited by postsynaptic alpha-2 receptors located on intestinal epithelial cells. Agents which selectively activate alpha-2 receptors in the gut may therefore be beneficial in treating gastric ulcers and diarrheal states. Two such agents which activate alpha-2 receptors in the gut are WHR-1370A [1-n-butoxy-3-(2,6-dimethylphenylcarbamoyl) guanidine hydrochloride] and lidamidine. WHR-1370A is a potent gastric antisecretory and antiulcer agent which inhibits the release of acetylcholine from the vagus nerve. WHR-1370A's activity is blocked by yohimbine. Lidamidine is a clinically effective antidiarrheal agent. Lidamidine's response is partially inhibited by yohimbine in animal diarrheal models. Alpha-2 agonists represent a new class of drugs which have a promising future in the treatment of gastrointestinal disorders.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic alpha-Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/Antidiarrheals,
http://linkedlifedata.com/resource/pubmed/chemical/Carbachol,
http://linkedlifedata.com/resource/pubmed/chemical/Clonidine,
http://linkedlifedata.com/resource/pubmed/chemical/Cysteamine,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxyglucose,
http://linkedlifedata.com/resource/pubmed/chemical/Gastrins,
http://linkedlifedata.com/resource/pubmed/chemical/Norepinephrine,
http://linkedlifedata.com/resource/pubmed/chemical/Phenylurea Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Yohimbine,
http://linkedlifedata.com/resource/pubmed/chemical/lidamidine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0024-3205
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
3
|
pubmed:volume |
35
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1031-42
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:6148675-Adrenergic alpha-Agonists,
pubmed-meshheading:6148675-Animals,
pubmed-meshheading:6148675-Antidiarrheals,
pubmed-meshheading:6148675-Brain,
pubmed-meshheading:6148675-Carbachol,
pubmed-meshheading:6148675-Clonidine,
pubmed-meshheading:6148675-Cysteamine,
pubmed-meshheading:6148675-Deoxyglucose,
pubmed-meshheading:6148675-Gastric Acid,
pubmed-meshheading:6148675-Gastrins,
pubmed-meshheading:6148675-Gastrointestinal Motility,
pubmed-meshheading:6148675-Humans,
pubmed-meshheading:6148675-Injections, Intraventricular,
pubmed-meshheading:6148675-Norepinephrine,
pubmed-meshheading:6148675-Peptic Ulcer,
pubmed-meshheading:6148675-Phenylurea Compounds,
pubmed-meshheading:6148675-Time Factors,
pubmed-meshheading:6148675-Yohimbine
|
pubmed:year |
1984
|
pubmed:articleTitle |
Alpha-2 receptors in the gastrointestinal system: a new therapeutic approach.
|
pubmed:publicationType |
Journal Article,
Review
|